NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Forecast, Price & News $3.10 +0.05 (+1.64%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$3.01▼$3.1650-Day Range$2.48▼$3.7952-Week Range$1.81▼$36.15Volume82,608 shsAverage Volume272,111 shsMarket Capitalization$93.31 millionP/E RatioN/ADividend YieldN/APrice Target$10.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Relmada Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside248.4% Upside$10.80 Price TargetShort InterestBearish2.25% of Shares Sold ShortDividend StrengthN/ASustainability-1.45Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.69) to ($3.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector335th out of 966 stocksBiotechnology Industry11th out of 40 stocks 3.2 Analyst's Opinion Consensus RatingRelmada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.80, Relmada Therapeutics has a forecasted upside of 248.4% from its current price of $3.10.Amount of Analyst CoverageRelmada Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.25% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Relmada Therapeutics has recently increased by 9.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRelmada Therapeutics has received a 66.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for mood disorders" product. See details.Environmental SustainabilityThe Environmental Impact score for Relmada Therapeutics is -1.45. Previous Next 2.7 News and Social Media Coverage News SentimentRelmada Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.Search Interest3 people have searched for RLMD on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.50% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.50% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($3.69) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Relmada Therapeutics (NASDAQ:RLMD) StockRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.Read More RLMD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLMD Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comHere's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn SituationSeptember 21, 2023 | finance.yahoo.comRelmada (RLMD) Up on Positive Data for Anti-Depressant CandidateOctober 4, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 20, 2023 | benzinga.comRelmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression StudySeptember 20, 2023 | marketwatch.comRelmada Therapeutics Shares Rise 18% After Positive Trial Data for REL-1017September 20, 2023 | markets.businessinsider.comRelmada Therapeutics: Long-term Study With REL-1017 Shows Rapid, Sustained Therapeutic EffectsSeptember 20, 2023 | finance.yahoo.comRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive DisorderSeptember 1, 2023 | msn.comRelmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim ReadoutOctober 4, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.August 23, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)August 16, 2023 | finance.yahoo.comFollowing a 88% decline over last year, recent gains may please Relmada Therapeutics, Inc. (NASDAQ:RLMD) institutional ownersAugust 9, 2023 | markets.businessinsider.comRelmada Therapeutics (RLMD) Gets a Buy from Mizuho SecuritiesAugust 9, 2023 | finanznachrichten.deRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsJune 21, 2023 | fool.comRelmada Therapeutics (NASDAQ: RLMD)June 8, 2023 | finance.yahoo.comRelmada Therapeutics to Participate in the Goldman Sachs Global Healthcare ConferenceJune 3, 2023 | benzinga.comROSEN, RESPECTED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMDJune 2, 2023 | finance.yahoo.comRelmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare ConferenceMay 24, 2023 | finance.yahoo.comRelmada Therapeutics Insider Ups Holding By 62% During YearMay 24, 2023 | finance.yahoo.comRelmada Therapeutics Insider Ups Holding By 62% During Year \May 24, 2023 | finance.yahoo.comRelmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual MeetingMay 15, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)May 12, 2023 | finanznachrichten.deRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 11, 2023 | markets.businessinsider.comMizuho Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)May 11, 2023 | msn.comRelmada Therapeutics: Q1 Earnings InsightsMay 11, 2023 | finance.yahoo.comRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 10, 2023 | benzinga.comEarnings Preview For Relmada TherapeuticsMay 9, 2023 | marketwatch.comRLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.See More Headlines Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Company Calendar Last Earnings8/08/2023Today10/04/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RLMD CUSIPN/A CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees14Year Founded2004Price Target and Rating Average Stock Price Forecast$10.80 High Stock Price Forecast$25.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+248.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-157,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-94.92% Return on Assets-86.33% Debt Debt-to-Equity RatioN/A Current Ratio11.40 Quick Ratio11.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.67 per share Price / Book0.66Miscellaneous Outstanding Shares30,100,000Free Float26,036,000Market Cap$93.31 million OptionableOptionable Beta0.13 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Sergio Traversa M.B.A. (Age 63)MBA, Pharm.D., PharmD, CEO & Director Comp: $719.04kMr. Maged S. Shenouda M.B.A. (Age 59)MBA, R.Ph, R.Ph., Chief Financial Officer Comp: $450.35kMr. Charles S. Ence CPA (Age 58)M.B.A., Chief Accounting & Compliance Officer Comp: $568.68kDr. Paolo Manfredi M.D. (Age 61)Ph.D., Chief Scientific Officer Ms. Gina DiGuglielmoVP & Head of Clinical OperationsDr. Marco Pappagallo M.D. (Age 64)Chief Clinical Officer Mr. John HixonHead of CommercialDr. Cedric O'Gorman M.B.A. (Age 47)M.D., MBA, Chief Medical Officer Dr. Richard M. Mangano (Age 73)Consultant More ExecutivesKey CompetitorsAnnexonNASDAQ:ANNXAthira PharmaNASDAQ:ATHANkartaNASDAQ:NKTXHomology MedicinesNASDAQ:FIXXSurface OncologyNASDAQ:SURFView All CompetitorsInsiders & InstitutionsBarclays PLCBought 131,161 shares on 9/21/2023Ownership: 0.485%Wolverine Trading LLCBought 10,300 shares on 8/23/2023Ownership: 0.000%Goldman Sachs Group Inc.Sold 37,477 shares on 8/15/2023Ownership: 0.539%Citadel Advisors LLCBought 44,300 shares on 8/15/2023Ownership: 0.000%Y Intercept Hong Kong LtdBought 42,574 shares on 8/15/2023Ownership: 0.141%View All Insider TransactionsView All Institutional Transactions RLMD Stock - Frequently Asked Questions Should I buy or sell Relmada Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RLMD, but not buy additional shares or sell existing shares. View RLMD analyst ratings or view top-rated stocks. What is Relmada Therapeutics' stock price forecast for 2023? 6 Wall Street analysts have issued 12 month target prices for Relmada Therapeutics' stock. Their RLMD share price forecasts range from $4.00 to $25.00. On average, they predict the company's stock price to reach $10.80 in the next twelve months. This suggests a possible upside of 248.4% from the stock's current price. View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts. How have RLMD shares performed in 2023? Relmada Therapeutics' stock was trading at $3.49 at the beginning of 2023. Since then, RLMD shares have decreased by 11.2% and is now trading at $3.10. View the best growth stocks for 2023 here. When is Relmada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our RLMD earnings forecast. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced its earnings results on Tuesday, August, 8th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.08. What ETF holds Relmada Therapeutics' stock ? AdvisorShares Psychedelics ETF holds 150,158 shares of RLMD stock, representing 5.18% of its portfolio. What is Relmada Therapeutics' stock symbol? Relmada Therapeutics trades on the NASDAQ under the ticker symbol "RLMD." How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Relmada Therapeutics' stock price today? One share of RLMD stock can currently be purchased for approximately $3.10. How much money does Relmada Therapeutics make? Relmada Therapeutics (NASDAQ:RLMD) has a market capitalization of $93.31 million. The company earns $-157,040,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis. How can I contact Relmada Therapeutics? Relmada Therapeutics' mailing address is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. The official website for the company is www.relmada.com. The company can be reached via phone at (786) 629-1376 or via email at mbecker@relmada.com. This page (NASDAQ:RLMD) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.